{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-261697","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.341623+00:00","generated_at":"2026-05-17T00:55:00.962936+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Kalaris Therapeutics appoints Matthew Gall as CFO effective November 3, 2025","bullets":["Matthew Gall appointed CFO and Treasurer effective Nov 3, 2025; succeeds Brett Hagan as principal financial officer.","Annual base salary of $485,000; eligible for target bonus of up to 40% of base salary.","Received incentive stock option for 235,000 shares vesting over 4 years at closing price on grant date.","Severance: 9 months salary (12 months if within 12 months of change in control) plus COBRA and accelerated equity.","Gall previously CFO of iTeos Therapeutics (June 2020 – Aug 2025)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-261697","json":"https://secwatch.observer/filing/0001193125-25-261697.json","markdown":"https://secwatch.observer/filing/0001193125-25-261697.md","text":"https://secwatch.observer/filing/0001193125-25-261697.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525261697/0001193125-25-261697-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525261697/d14509d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:55:00.962936+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}